• Athenex rakes in $100M, sets up Chinese TCR-focused JV fiercebiotech
    July 09, 2018
    Just over a year since its IPO, Athenex is broadening its scope—the biotech is picking up a $100 million investment from Perceptive Advisors, licensing a modified cancer-fighting enzyme and launching a new Chinese joint venture built around T-cell recepto
PharmaSources Customer Service